Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment

Abstract

Stomach adenocarcinoma (STAD) ranks as the fourth prevalent cause of mortality worldwide due to cancer. The prognosis for those suffering from STAD was bleak. Immunogenic cell death (ICD), a form of induced cellular death that causes an adaptive immune response and has increasing in anticancer treatment. However, it has not been ascertained how ICD-related lncRNAs affect STAD. Using univariate Cox regression and the TCGA database, lncRNAs with prognostic value were identified. Thereafter, we created a prognostic lncRNA-based model using LASSO. Kaplan-Meier assessment, time-dependent receiver operating characteristic (ROC) analyzation, independent prognostic investigation, and nomogram were used to assess model correctness. Additional research included evaluations of the immunological microenvironment, gene set enrichment analyses (GSEA), tumor mutation burdens (TMBs), tumor immune dysfunctions and exclusions (TIDEs), and antitumor compounds IC50 predictions. We found 24 ICD-related lncRNAs with prognostic value via univariate Cox analysis (p < 0.05). Subsequently, a risk model was proposed using five lncRNAs relevant to ICD. The risk signature, correlated with immune cell infiltration, had strong predictive performance. Individuals at low-risk group outlived those at high risk (p < 0.001). An evaluation of the 5-lncRNA risk mode including ROC curves, nomograms, and correction curves confirmed its predictive capability. The findings of functional tests revealed a substantial alteration in immunological conditions and the IC50 sensitivity for the two groups. Using five ICD-related lncRNAs, the authors developed a new risk model for STAD patients that could predict their cumulative overall survival rate and guide their individual treatment.

Immune cell death-related lncRNA signature as a predictive factor of clinical outcomes and immune checkpoints in gastric cancer

“…Gastric cancer cells can Frontiers in Pharmacology frontiersin.org avoid monitoring and attack by the immune system (Schreiber et al, 2011). Immune evasion is closely associated with the immune microenvironment, which could become a new aspect of research on gastric cancer treatment (Wang et al, 2021b;Ding et al, 2022;Gao et al, 2022;Han et al, 2022;Liao et al, 2022;Xu et al, 2022). Therefore, we analyzed the effect of ICD-related gene mutations on immune cell Frontiers in Pharmacology frontiersin.org 10 infiltration in the high-and low-risk groups and found that there were statistically significant differences between the two groups in many immune cells.…”

“…Ding et al screened five lncRNAs based on 34 ICD-related genes to construct a prognostic model for gastric adenocarcinoma. The model could predict the cumulative survival rate and guide individual treatment ( Ding et al, 2022 ). The aforementioned studies all indicated that ICD was closely related to lncRNAs and to disease prognosis.…”

Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma

“…Due to the lack of apparent symptoms in the early stages of GC, many patients are diagnosed at advanced stage 5 , 6 . STAD is the most common and malignant subtype 7 . Surgery remains the cornerstone of GC treatment.…”

A comprehensive analysis of the significance of immunogenic cell death-related genes in the prognosis and immune microenvironment of patients with bladder cancer

“…Immunogenic cell death (ICD), which enhances tumor activation by the immune system of an immunoactive host, is a speci c variant of regulatory cell death [7]. It is driven by stress and can induce adaptive immunity against dead cell antigens, similar to the host immune system's second strike against tumor cells [8].…”